Encapon 200 Special Precautions

Cardiovascular: Orthostatic hypotension and syncope may occur.
Concomitant Use: Use of non-selective MAOI inhibitors (eg, phenelzine, tranylcypromine) should generally be avoided.
Dermatologic: Increased risk of developing melanoma; monitoring recommended.
Gastrointestinal: Diarrhea and colitis (primarily lymphocytic) have occurred; discontinue use and institute appropriate therapy with prolonged diarrhea.
Musculoskeletal: Severe rhabdomyolysis has been reported.
Neurologic: Falling asleep during activities of daily living, with or without somnolence, has been reported; discontinuation recommended.
Neurologic: Abrupt discontinuation or dose reduction may result in a symptom complex similar to neuroleptic malignant syndrome.
Neurologic: New onset or exacerbation of dyskinesia may occur.
Psychiatric: Compulsive behaviors and impaired impulse control have been reported; monitoring recommended and dose reduction or discontinuation may be necessary.
Psychiatric: New or worsening changes in mental status or behaviour, which may be severe and include psychotic behavior, have been reported.
Psychiatric: Avoid use in patients with major psychotic disorder.
Renal: Retroperitoneal fibrosis has been reported with ergot-derived dopaminergic therapy; may resolve with discontinuation.
Respiratory: Pulmonary fibrosis has occurred with entacapone, and other fibrotic complications (including retroperitoneal fibrosis, pulmonary infiltrates, pleural effusion, and pleural thickening) have been reported with ergot-derived dopaminergic therapies; may resolve with discontinuation.
Concurrent levodopa dose may need to be reduced by about 10-30% · ischaemic heart disease.
HEPATIC IMPAIRMENT: Manufacturer advises avoid.
TREATMENT CESSATION: Avoid abrupt withdrawal.